Epidemics of recent emerging infectious diseases, such as the H1N1 pandemic, demand cost-efficient and scalable production technologies that can rapidly deliver effective therapeutics to clinics. Traditional vaccine manufacturers have trouble meeting these needs, as their manufacturing processes are slow and not economically scalable. Developing world populations are especially burdened by lack of access to effective and inexpensive therapies.
This team is developing SwiftVax, a plant production platform that produces animal and human vaccines efficiently and affordably. The technology can rapidly produce large amounts of therapeutics with minimal investment compared to traditional vaccine production infrastructure.
This grant will help in developing a proof-of-concept that will bring SwiftVax-produced vaccines closer to market. The team’s initial target product is an animal vaccine for Newcastle Disease, a devastating and highly pathogenic disease in poultry. The disease threatens commercial poultry in developed countries as well as the livelihood of disadvantaged populations in Africa, to whom chickens represent the main source of food and income.
University of California, Berkeley, 2004 - $20,000
This E-Team developed a prototype device for removing arsenic from Bangladesh's drinking water. The device uses chemically treated bottom ash (residue left over from coal combustion) as the medium for removing arsenic. The invention is based on coating the surfaces of bottom ash particles with ferric hydroxide, and using this treated ash to react with, remove, and immobilize arsenic in water supplies. Lab results demonstrated that 5 gm of treated bottom ash can reduce arsenic concentration in 2.4 liters of water from 2400 ppb to 10 ppb.
The E-Team believes the final product’s pricing model will be proportional to table salt, costing <.30/kg per person per year. The business costs are also comparable to table salt.
The team consisted of four lab-based professionals in chemical engineering and physics.